Eileen M. O'Reilly, MD, FASCO - Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management

About this episode

The episode discusses redefining precision oncology in pancreatic cancer through emerging KRAS-targeted strategies.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027. Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Revolution Medicines. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guest: Eileen M. O'Reilly, MD, FASCO

Topics covered

• Precision Oncology
• Pancreatic Cancer
• KRAS-Targeted Strategies
• Clinical Management
• Healthcare Education

Keywords

• pancreatic cancer
• precision oncology
• KRAS
• clinical management
• continuing education

Sponsors

Revolution Medicines

Mentioned in this episode

Organizations: PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education, Accreditation Council for Pharmacy Education, American Nurses Credentialing Center

More episodes of PeerView Gastroenterology CME/CNE/CPE Video Podcast

• Anita Afzali, MD, MPH, MHCM, FACG, AGAF / Jessica R. Allegretti, MD, MPH, FACG, AGAF / Millie D. Long, MD, MPH - At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition · May 29, 2026 · 1h 11m
• Yelena Y. Janjigian, MD*, Marion Liu, MD - Unifying Surgical-Oncology Expertise in Resectable Gastric/GEJ Malignancies: Leveraging the Evidence on Perioperative Immunotherapy Platforms to Deliver Personalized Care · April 3, 2026 · 1h 4m
• Tanios Bekaii-Saab, MD, FACP, FASCO - Raising the Game in Biliary Cancer: Adapting Rapidly Emerging Evidence and Achieving Optimal Disease Control With FGFR-Targeted Platforms · April 3, 2026 · 35 min
• Mrinal Gounder, MD - Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice · April 1, 2026 · 1h 0m
• Samuel Cytryn, MD / Daniela Molena, MD / Manish A. Shah, MD, FASCO - Synchronizing Success in Resectable Gastric/GEJ Cancer: Merging Expertise to Effectively Deliver Immunotherapy Platforms in the Surgical Setting · March 4, 2026 · 1h 0m
• Prof. Dr. Peter R. Galle - Streamlining Multidirectional Care in HCC: Applying Groundbreaking Evidence on Systemic Treatment Approaches Across the Disease Spectrum · February 12, 2026 · 1h 33m